PHARMACODYNAMICS OF MULTIPLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN CONTROLLED ASTHMATIC PATIENTS.

Fowler A.; Hilbert J.; Koenen R.; Kappeler D.; Wood C.; Gupta A.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >PHARMACODYNAMICS OF MULTIPLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN CONTROLLED ASTHMATIC PATIENTS.

【24h】

PHARMACODYNAMICS OF MULTIPLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN CONTROLLED ASTHMATIC PATIENTS.

机译：BI 1021958（一种新型CRTH2拮抗剂）在受控哮喘患者中的多次口服剂量的药动学。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2016年第1期|共1页
作者
Fowler A.; Hilbert J.; Koenen R.; Kappeler D.; Wood C.; Gupta A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. PHARMACODYNAMICS OF MULTIPLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN CONTROLLED ASTHMATIC PATIENTS. [J] . Fowler A., Hilbert J., Koenen R., Clinical Pharmacology and Therapeutics . 2016,第Suppla1期

机译：BI 1021958（一种新型CRTH2拮抗剂）在受控哮喘患者中的多次口服剂量的药动学。
2. SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN HEALTHY CHINESE AND JAPANESE MALES. [J] . Jang I., Kim J., Koenen R., Clinical Pharmacology and Therapeutics . 2016,第Suppla1期

机译：BI 1021958（一种新型CRTH2拮抗剂）在中国健康人群和日本人中的安全性，耐受性，药代动力学和药代动力学。
3. SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN HEALTHY MALE VOLUNTEERS. [J] . Koenen R., Fowler A., Gupta A., Clinical Pharmacology and Therapeutics . 2016,第Suppla1期

机译：BI 1021958（一种新的CRTH2拮抗剂）在健康男性志愿者中的单剂量口服剂量的安全性，耐受性，药代动力学和药物动力学。
4. Oral Mycophenolate Mofetil Dose Escalation Trial Assessing Adverse Effects and Pharmacodynamic Responses in Normal Dogs (Abstract P14) [C] . Conference of the American College of Veterinary Internal Medicine (ACVIM) . 2017

机译：口服霉霉素Mofetil剂量升级试验评估正常狗的不利影响和药物动力学反应（摘要P14）
5. The pharmacodynamics of antimicrobial agents against clinical isolates of Staphylococcus epidermidis in a multiple-dose in vitro pharmacodynamic model [D] . Findlay, Ian Masuce 2001

机译：在多剂量体外药效学模型中，抗菌药物对表皮葡萄球菌临床分离株的药效学
6. Safety Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 655064 an Antagonistic Anti‐CD40 Antibody in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases [O] . Christian Schwabe, Bernd Rosenstock, Thi Doan, -1

机译：对抗性抗CD40抗体BI655064的多种上升剂量在健康受试者中的安全性药代动力学和药效学：一种针对自身免疫性疾病的潜在新疗法
7. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment [O] . Hall Ian P., Fowler Andrew V., Gupta Abhya, 2015

机译：口服CRTH2拮抗剂BI 671800在控制不佳的哮喘（作为唯一控制者）和吸入性糖皮质激素治疗下的疗效
8. Results of a 28-Day Repeated Dose Oral Toxicity Study in Wistar Rats and a 14-Day Dose Range Finding Study by Oral Gavage in Wistar Rats with Lithium-bis(oxalato)borate(LiBOB 1). [R] . 2012

机译：在Wistar大鼠中进行28天重复剂量口服毒性研究的结果和在具有锂 - 双（草酸根）硼酸盐（LiBOB 1）的Wistar大鼠中通过口服管饲进行的14天剂量范围发现研究。

PHARMACODYNAMICS OF MULTIPLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN CONTROLLED ASTHMATIC PATIENTS.

著录项

相似文献

相关主题

期刊订阅